Sponsor

Phase

US Department of Veterans Affairs

VA Office of Research and Development

Applicant

Tradename

Generic Name

Dosage

NDA

Approval Date

Type

RLD

Patent No.

Patent Expiration

Product

Substance

Delist Req.

Exclusivity Expiration

Watson Labs

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

hydralazine hydrochloride; hydrochlorothiazide; reserpine

TABLET;ORAL

083770-001

Approved Prior to Jan 1, 1982

DISCN

⤷ Start Trial

>Applicant

>Tradename

>Generic Name

>Dosage

>NDA

>Approval Date

>TE

>Type

>RLD

>RS

>Patent No.

>Patent Expiration

>Product

>Substance

>Delist Req.

>Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Last updated: February 12, 2026

Hydrochlorothiazide combined with reserpine and hydralazine targets hypertension management, primarily in older adult populations. Market considerations involve incumbent drug competition, regulatory status, patent landscape, and evolving treatment guidelines.

Market Overview

Hydrochlorothiazide (HCTZ) remains one of the most prescribed diuretics for hypertension. Reserpine, an alkaloid derived from Rauwolfia serpentina, was historically significant but has declined due to neuropsychiatric side effects. Hydralazine, a direct-acting vasodilator, is reserved for resistant hypertension or specific indications.

The combination therapy's use has waned, primarily replaced by newer antihypertensives with better safety profiles, including ACE inhibitors, ARBs, and calcium channel blockers.

Market Size and Trends

Global Hypertenion Market: Valued at approximately USD 33 billion in 2022, expected to grow at 7% annually, reaching around USD 50 billion by 2030 ([1]).
Role of Combination Drugs: Account for roughly 30% of antihypertensive prescriptions.
Hydrochlorothiazide with Reserpine and Hydralazine: No recent standalone market data; historical formulations now face decline due to safety concerns and newer alternatives.

Regulatory and Patent Landscape

Regulatory Status: The drugs are available as generics. Reserpine’s label restrictions limit use, prescriber caution is common.
Patents: Most patents expired decades ago; exceptions are minimal, reducing barriers to generic manufacturing.
Off-label Use and Approvals: Limited approval for combination formulations; often prescribed as individual agents.

Key Factors Affecting Market Dynamics

Safety Profile Concerns: Reserpine linked to depression; hydralazine associated with lupus-like syndrome.
Pricing and Reimbursement: Low-cost generics; high volume but decreasing due to reduced prescribing.
Competitor Landscape: Dominance of fixed-dose combinations like amlodipine-valsartan drives market share away from older drug combinations.

Financial Trajectory

Historical Revenue: Prescriptions peaked in the 1980s and 1990s. Current revenue for this specific combination has declined sharply.
Current Market Activity: Minimal; most revenues are from generic sales for individual components.
Forecast: The combination drug's sales are projected to decline further, possibly near zero as formulary restrictions and safety concerns limit use ([2]).

Future Outlook

Shift continues toward safer, better-tolerated antihypertensives.
New fixed-dose combinations and personalized medicine approaches are replacing older therapies.
Limited pipeline development for reserpine-based formulations due to safety and regulatory issues.

Key Takeaways

The combination of hydrochlorothiazide, reserpine, and hydralazine has witnessed a steep decline in market relevance.
The global hypertension market continues to grow, primarily driven by newer, safer medication classes.
Patent expiration, safety issues, and robust competition have rendered this combination increasingly obsolete.
Revenue and sales trajectories for this combination are trending toward negligible levels.
Future prospects for this specific combination are minimal unless new formulations addressing safety concerns emerge.

Frequently Asked Questions

1. Why has the market for hydrochlorothiazide with reserpine and hydralazine declined?
Their decline results from safety concerns, especially reserpine's psychiatric side effects, and the advent of newer antihypertensive drugs with superior safety and efficacy profiles.

2. Are there ongoing regulatory restrictions for reserpine-containing formulations?
Yes. Many regulatory agencies recommend cautious use due to side effects, and some formulations are not marketed in certain regions.

3. Can reserpine or hydralazine formulations rebound in the market?
Unlikely, absent significant safety-related breakthroughs or novel delivery methods that mitigate adverse effects; current trends favor newer agents.

4. What alternative drugs are replacing older combination therapies for hypertension?
ACE inhibitors, ARBs, calcium channel blockers, and RAAS inhibitors comprise the primary replacements for older diuretics and vasodilators.

5. Is there any R&D interest in reserpine-based compounds?
R&D interest is minimal, focusing instead on new molecules with improved safety profiles or targeted mechanisms.

References

[1] Grand View Research, "Hypertension Drugs Market Size & Trends," 2022.
[2] IQVIA, "Global Medicine Sales Data," 2022.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
Patent Applications:	1
DailyMed Link:	HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE at DailyMed

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE Drug Patent Profile

Which patents cover Hydrochlorothiazide W/ Reserpine And Hydralazine, and when can generic versions of Hydrochlorothiazide W/ Reserpine And Hydralazine launch?

AI Deep Research

Questions you can ask:

Summary for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

Recent Clinical Trials for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

Market Dynamics and Financial Trajectory for Hydrochlorothiazide with Reserpine and Hydralazine